Species |
Human |
Protein Construction |
SLAMF7/CRACC/CD319 (Ser23-Met22) Accession # Q9NQ25-1 |
His |
Avi |
N-term |
|
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized SLAMF7/CRACC/CD319[Biotin], His & Avi, Human at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind AntiSLAMF7 Antibody, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
25.3 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
![SLAMF7/CRACC/CD319[Biotin], His & Avi, Human SLAMF7/CRACC/CD319[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z04616 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z04616 ELISA.jpg)
Immobilized SLAMF7/CRACC/CD319[Biotin], His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.6 ng/ml determined by ELISA.
![SLAMF7/CRACC/CD319[Biotin], His & Avi, Human SLAMF7/CRACC/CD319[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z04616 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z04616 HPLC.png)
The purity of SLAMF7/CRACC/CD319[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
![SLAMF7/CRACC/CD319[Biotin], His & Avi, Human SLAMF7/CRACC/CD319[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z04616 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z04616 PAGE.png)
SLAMF7/CRACC/CD319[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. |
Synonyms |
CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.